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Naturally processed peptides were acid extracted from immunoaffinity-purified HLA-DR2, DR3, 
DR4, DR7, and DRS. Using the complementary techniques of mass spectrometry and Edman 
microsequencing,  >200 unique peptide masses were identified from each allele, ranging from 
1,200 to 4,000 daltons (10--34 residues in length), and a total of 201 peptide sequences were 
obtained.  These peptides  were derived from 66 different source proteins  and represented  sets 
nested at both the amino- and carboxy-terminal  ends with an average length of 15-18 amino 
acids. Strikingly,  most of the peptides  (>85%) were derived from endogenous proteins  that 
intersect the endocytic/class II pathway, even though class II molecules are thought to function 
mainly in the presentation of exogenous foreign peptide antigens. The predominant endogenous 
peptides were derived from major histocompatibility complex-related molecules. A few peptides 
derived from exogenous bovine serum proteins were also bound to every allele. Four prominent 
promiscuous self-peptide sets (capable of binding to multiple HLA-DR alleles) as well as 84 
allele-specific  peptide sets were identified. Binding experiments confirmed that the promiscuous 
peptides have high affinity for the binding groove of all HLA-DR alleles examined. A potential 
physiologic role for these endogenous self-peptides as immunomodulators of the cellular immune 
response is discussed. 
MH  C class I and II molecules are membrane-bound gly- 
coproteins  that present  processed antigen to T  cells 
and initiate an immune response (1). Crystallographic  anal- 
ysis of several class I molecules identified a groove composed 
of two ct helices supported by an eight-strand/J-pleated  sheet 
containing electron-dense material that represents bound an- 
tigenic peptide (2-4). Several groups have characterized the 
complex mixtures of acid-extracted class I-bound peptides 
by HPLC fractionation and sequencing (5-9). The majority 
of these peptides were 8-11 amino acids long and possessed 
a binding motif characteristic of peptides that bind to a given 
class I allele. 
The characterization of naturally processed peptides bound 
to class II molecules provides an approach  towards  under- 
standing both antigen processing and peptide binding events 
in vivo. The stability of class II molecules requires peptide 
binding (10, 11); however, the precise class II molecule--pep- 
tide contacts that provide this energy are not yet well defined. 
Identification of naturally processed peptides extracted and 
sequenced from class II molecules revealed that the bound 
peptides were longer (13-25 residues) than those bound to 
class I  (12-15) and nested  at  the amino- and/or carboxy- 
terminal ends, suggesting that the peptide binding groove 
on class II molecules is open at both ends (13, 15). Although 
only a limited number of source proteins were reported, pep- 
tides derived from both endogenous proteins and exogenous 
serum proteins were identified. The association  constants (mea- 
sured by competitive inhibition) for several of these peptides 
were in the nanomolar range, confirming the high affinity 
of these peptides  for class II molecules. 
To further our understanding of class II antigen processing 
and peptide binding, several different allelic  forms of HLA-DR 
molecules were purified and the bound peptides were identified 
using the complementary techniques of mass spectrometry 
and Edman microsequencing.  Each allele has a complex, yet 
readily distinguishable and reproducible peptide profile. The 
range of peptide masses is comparable among the alleles ex- 
amined. To establish a representative collection of bound pep- 
tides and to identify their respective source proteins, individual 
fractions corresponding to both major and minor chromato- 
graphic peaks from the extracted peptide pool separations were 
chosen for sequence analysis. Various features relating to the 
allelic specificity and promiscuity of naturally processed pep- 
tides bound to different DR alleles will be described. 
Materials and Methods 
Reagents and  Materials.  HLA-DR  molecules were purified 
from homozygous EBV-transformed  human B lymphocyte  lines: 
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Volume 178  July 1993  27-47 DR1 (DRBI*0101) from LG-2 and HOM-2 cells, DR2b/DR2a 
(DRBI*1501/DRB5*0101)  from  MST  cells, DR3/DRw52 
(DRBI*0301/DRB3*0201)  from  WT20  cells, DR4/DRw53 
(DRBI*0401/DRB4"0101)  from  Priess cells, DR7/DRw53 
(DILBI*0701/DRB4*0101)  from  Mann  cells  and  DR.8 
(DRBI*0801) from 23.1 cells. DR1 was also  purified  from the MHC 
antigen-loss mutant cell lines 721.45 (kindly provided by Robert 
DeMars, University  of  Wisconsin, Madison,  WI) and 721.221 (CRL 
1855; American Type Culture Collection, Rockville, MD). The 
cells were grown in RPMI 1640 supplemented with 10% FCS, 
2 mM ghtamiue, 50 U/ml penicillin  G, and 50 #g/ml streptomycin 
in spinner flasks or roller bottles and stored as pellets at  -80~ 
The anti-HLA-DR hybridoma LB3.1 (IgG2b) was produced in 
this laboratory (16). The anti-HLA-DRw53 mAb 109d6 (17) was 
kindly provided by R. Winchester (Columbia University, New 
York, NY). 
Peptides representing residues 97-120 of the invariant chain (Ii) 
(LPKPPKPVSKMRMATPLLMQALPM), residues 182-198  of 
HLA-DR o~ chain (APSPLPETTENWCALG),  residues 188-202 
of the Ig ~ chain C region (KHKVYACEVTHQGLS), residues 
103-117 of the HLA-A2-1ike  sequence (VGSDWRFLRGYHQYA), 
and residues 1273-1291 of  bovine apolipoprotein B-100 (IPDNLF- 
LKSDGRIKYTLNK) were synthesized on a peptide synthesizer 
(430; Applied Biosystems,  Inc., Foster City, CA) using solid-phase 
Fmoc/HBTU chemistry. Biotinylations were done on resin-bound 
free amino-terminal peptides. Briefly, a fivefold molar excess of 
N-hydroxysuccinimidyl-crosslinked  biotin  (Pierce Chemical Co., 
Rockford, IL) was added to a 5-mg/ml suspension of resin-bound 
peptide in imidazole-buffered  DMSO and rocked at room temper- 
ature for 2 h. The slurry was then washed four times with 25 ml 
of  DMSO followed  by four washes with 50 ml HPLC-grade water, 
air dried, and stored at 4QC until deprotection/cleavage.  All pep- 
tides were purified by HPLC (HPXL solvent delivery system with 
UV-M detector; Rainin Instrument Co., Inc., Woburn, MA) on 
a preparative Cls reversed-phase chromatography (tLPC)  1 column 
(25  x  2.2 cm, 300 A, 10-15 #m; Vydac, Hesperia, CA) in 0.06% 
TFA/water with a 20-80%  50-min linear 0.055% TFA/acetoni- 
trile  gradient.  The  integrity  of  the  purified peptides was 
confirmed by amino acid analysis (420A/130A derivatizer/HPI.C 
after hydrolysis  with 6 N HC1 for 24 h in vacuo; Applied  Biosystems, 
Inc.) and mass spectrometry on a triple quadrupole mass spectrom- 
eter equipped with an electrospray  ion source (ESI-MS) (TSQ 700; 
Finnigan MAT, San Jose, CA). 
Protein Purification.  Immunoafl~nity  purification of HLA-DR 
alleles was performed as reported (18) with minor modifications. 
The detergent-soluble  lysates  from Priess and Mann cells  were loaded 
onto an immunoaftinity column prepared with the mAb 109d6 
to remove the DtLw53 (DRB4*0101) allele-linked molecules be- 
fore passage through the LB3.1 immunoa~nity column. DRw52 
(DRB3*0201) was not removed from the WT-20 lysates and is a 
minor contaminant (<10%) of the DR3 preparations. Similarly, 
the DR2 preparations contain both the major and minor isotypes: 
DR2a (DRB5*0101) and DR2b (DRB1*1501). 
Water-soluble HLA-DR was produced by limited papain diges- 
tion, as prepared for the crystallization  of  HLA-DR molecules,  then 
purified using gel filtration, concentrated  by vacuum dialysis  to ~10 
mg/ml, and stored at 4~  (19). SDS-PAGE was performed by the 
method of Laemmli (20) with the single modification that samples 
were not boiled before analysis.  Protein concentrations were deter- 
mined by bicinchoninic acid assay (Pierce Chemical Co.) and/or 
quantitative amino acid analysis (Applied Biosystems, Inc.). Im- 
1 Abbreviation used in this paper: RPC, reversed-phase chromatography. 
mediately before peptide extraction protein samples were further 
purified by HPLC (6000A solvent delivery system; Waters, Mil- 
ford, MA) on a size-exclusion column (300  x  7.5 ram, 250 -~, 
10 #m, TSK-3000SW; Toyo Soda, Philadelphia, PA) in 25 mM 
2-[N-morpholino] ethanesulfonic acid, 150 mM NaC1, pH 6.5, at 
a flow rate of 1 ml/min and spin-concentrated using Centricon 
10 ultrafiltration devices (Amicon, Danvers, MA) to remove any 
residual small molecular weight contaminants. 
Peptide Extraction and Separation.  All protein samples (1 mg) were 
spin-concentrated to a final  volume between 50 and 100 #1 using 
Centricon 10 ultrafiltration devices. Bound peptides were eluted 
from HLA-DK by addition of acetic acid (10%, 1 ml) and incuba- 
tion at 70~  for 15 min. Isolation ofpeptide pools from HLA-DK 
was accomplished  by ultrafiltration. The acid-denatured  protein was 
retained in the Centricon 10 microconcentrators, while extracted 
peptides were collected from the flow-through. The peptide pools 
were vacuum concentrated to 50 #1 in a Speed-Vac (Savant Instrs., 
Inc., Farmingdale, NY) before HPLC separation. 
Peptides were separated  by HPLC (Rainin Instrument Co. Inc.) 
on a microbore Cls RPC column (250 x  2.1 mm, 300 A, 5 #m; 
Vydac) as previously  described (15). Chromatographic analysis  was 
monitored at multiple UV wavelengths simultaneously, permit- 
ting spectrophotometric evaluation of purified species  before mass 
spectral and sequence analyses. Fractions were collected and stored 
at  -20~  until subsequent analyses. A sample of 25 mM MES 
was processed in parallel from the extraction procedure through 
the HPLC analysis  for each allele to control for possible contami- 
nation from reagents or materials. 
Mass Spectrometry and Edman Sequence Analyses.  R.PC  fractions 
were chosen for mass spectrometry analyses  based on UV absorp- 
tion profiles. Briefly,  optimum fractions from the RPC separation 
were chosen based on differential  UV absorbance at 210, 254, 277, 
and 292 nm, peak symmetry, and resolution (21). Selected frac- 
tions were further analyzed  by matrix-assisted  laser-desorption  mass 
spectrometry (MALD-MS) to determine the individual  mass values 
for the predominant peptides. 4% (4 #1) of the collected fractions 
was mixed with 1 #1 of matrix (c~-cyano-4-hydroxycinnamic  acid, 
10 mg/ml in 50% acetonitrile; Sigma Chemical Co., St. Louis, 
MO), applied to a gold plated sample disc, and dried. Mass deter- 
minations were made using a LASE MAT mass spectrometer (Fin- 
nigan MAT). Selected  fractions were analyzed by sample infusion 
using a TSQ 700 triple quadrupole mass spectrometer. 
Amino-terminal sequence analysis was accomplished by auto- 
mated Edman microsequencing using a pulsed-liquid protein se- 
quencer (477A; Applied  Biosystems,  Inc.). The resultant  phenylthio- 
hydantoin amino acid derivatives were identified manually using 
an on-line HPLC (120A; Applied  Biosystems,  Inc.). Initial sequence 
yields measured  in picomoles  were used to determine the total yield 
of peptides derived from single source proteins. Combining the 
mass spectral data with the sequencing analyses enables crucial 
verification  of both the amino- and carboxy-terminal amino acids 
of peptides within a single sample. For example, given a low 
picomolar mixture of two theoretical peptides, SMILE and SMIL, 
the presence of the carboxy-terminally truncated peptide SMIL 
would not be apparent by conventional Edman microsequencing 
alone. The observed sequence data would be SMILE  and any reduc- 
tion in yield of the carboxy-terminal residue could be attributed 
to normal losses during procession of the chemistry. All identified 
peptides were aligned to regions of proteins stored in the database 
using the BLAST network at the National Center for Biotech- 
nology Information (22). 
Peptide Binding.  The assay was performed as described previ- 
ously (23, 24). Briefly, 5  x  106 ceils were resuspended in 3% 
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followed by a wash with 50 ml PBS. Residual paraformaldehyde 
was quenched by addition of 5 mM glycylglycine  (incubated at room 
temperature  for 5 min)  and  washed with  another  50 ml PBS. 
2  x  10  s cells were  next  resuspended  in  100  #1  of complete 
medium, added to 100/~1 PBS containing biotinylated peptide, and 
incubated at 37~  for 10 h. Cells were then washed and stained 
with FITC-streptavidin  (4.22/~g/ml PBS, 0.1% BSA) at 4~  for 
30 min.  Each incubation  was followed by two washes with 250 
#1 PBS, 0.1%  BSA at 4~  Stained cells were subjected to flow 
cytometry on a FACScan  |  analyzer  (Becton  Dickinson  & Co., 
Mountain View, CA). To measure the relative amount of fluorescei- 
nated streptavidin bound, the mean fluorescence of 10,000 stained 
cells was determined. 
Comparison of different homozygous B lymphoblastoid cells for 
their  relative peptide binding  capacity was done by normalizing 
the  class  II  expression  levels using  biotinylated  LB3.1 mAb. 
Specificity was demonstrated  by blocking using  the L243 anti- 
HLA-DR  mAb  and/or  by competition  with  nonbiotinylated 
peptide. 
Results 
Peptide Isolation  from Immunoafflnity-tmrified HLA-DR Alleles 
The bound peptide pools were released from 1 mg of DR2, 
DR3,  DR4, DR7, and DR8 (~16 nmol) by acid elution 
with the total extracted peptide yields (--11-13 nmol, 70-80% 
recovery) for each DR allele similar to those previously de- 
scribed for DR1 (15). Moreover, purified DR molecules were 
stable ot/B complexes (>95% in each case), as measured by 
SDS-PAGE, indicating  that  the starting  material  was fully 
loaded with peptide (10, 25, 26); no separate ot and ~ chains 
were detectable in any preparation.  Only single free a  and 
chains were observed after acid elution of peptides,  sug- 
gesting the complete extraction of peptides (data not shown). 
Separations of the respective peptide pools were achieved 
using RPC and the peptide profiles from multiple  extrac- 
tion/separations  for each of the five alleles were highly re- 
producible. These profiles exhibit the complexity of the bound 
peptide pools and the differences highlight  the selectivity of 
individual peptides for specific alleles  (Fig.  1).  The bound 
peptides from papain-digested and detergent-solubilized DR 
had identical HPLC profiles. To confirm that papain solubili- 
zation of HLA-DR did not generate or alter the bound pep- 
tide  repertoire,  the  predominant  peaks  from  both  the 
detergent-soluble and papain-digested DR1 profiles were ana- 
lyzed and found to contain  peptides identical in mass and 
sequence (15). 
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Figure  1.  Reversed-phase  HPI.C separation profiles  ofpeptide pools  ex- 
tracted from papain-digested HI.A-DR. Each chromatogram represents 
the peptide repertoire as detected by UV absorbance  for both 210 (semi- 
tivity) and 277 nm (tryptophan/tyrosine content) at a fun scale absor- 
bance of 200 mAU. The profile  patterns differ  substantially, thus representing 
the various peptide fingerprints associated  with each DR allele. (A) Pep- 
tides bound to DR2, including two prominent peaks at 75 and 81 rain 
that were identified  by sequence  and mass analyses  as amino-terminal frag- 
ments (papain overdigestion  products) of the DtL2a and DR2b B chain, 
respectively; (B) peptides bound to DR3; (C) peptides bound to DR4; 
(D) peptides bound to DR7; (E) peptides bound to DRS; (/7) mock ex- 
traction buffers. The peak in B-E at ~50 min with a high 277-nm absor- 
bance was identified as an  organic contaminant from the Centricon 
ultrafiltration devices. 
Size Distribution of Allele-specific Peptide Pools 
Aliquots  from  the individual  RPC  separation  fractions 
(20-200 fmol) were analyzed by MALD-MS and 1,101 unique 
masses were identified from the peptide pools extracted from 
the five DR alleles (an average of 220/aUele).  Many individual 
fractions contained multiple  species of varying mass,  indi- 
cating codution of peptides in single chromatographic peaks, 
further corroborating the complexity of the separated mix- 
tures.  The molecular mass distribution  and estimated pep- 
tide length  (based on an amino  acid average mass value of 
118 chitons) varied from 1,239 to 4,091 daltons (10-34 residues 
in length)  with  the mode lying between  1,700 and 2,100 
daltons  (15-18 residues) for each allele  (Fig.  2). 
Identification and Sequence Characterization of Naturally 
Processed Bound Peptides 
Complete sequences for 201 peptides isolated from five DR 
alleles were obtained by automated Edman microsequencing 
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Figure 2.  Size distribution of peptides bound to different  HLA-DR 
alleles. A minimum  aliquot (see text) was removed  from each  RPC frac- 
tion containing  peptidic material  and analyzed  by MALD-MS. The mo- 
lecular masses  are plotted against the number  of isolated peptides  for each 
allele. Peptide length was estimated  by dividing the experimental  mass 
by an average  amino acid mass of 118 daltons. The mass range varied  be- 
tween 1,200 and 4,100 daltons with the mode lying between 1,700 and 
2,100 daltons of each allele. 
in combination with mass spectrometry. Source proteins of 
the sequenced peptides were identified by homology search 
of the current database (22, 27). Over 29 peptides were charac- 
terized from each DR allele.  Partial sequences for an addi- 
tional 94-110 peptides from unknown source proteins were 
also  obtained. 
The predominant source proteins of the naturally processed 
peptides sequenced from the class II molecules of human B 
cells were MHC-related molecules. Self-peptides derived from 
MHC class I and/or II molecules were isolated from every 
class II allele, including peptides derived from the three class 
I isotypes (HLA-A, HLA-B, and HLA-C) as well as from 
the three class II isotypes (HLA-DR, HLA-DQ, and HLA- 
DP).  From 201  sequenced peptides,  78 were derived from 
class I molecules, class II molecules, or the invariant chain 
(Ii). In addition, the relative abundance of these MHC-related 
self-peptides, as measured by initial yields from sequencing 
analyses,  was the highest observed. 
Peptides Identified  in a Single Allele.  Peptides derived from 
44 integral membrane proteins (including two EBV-encoded 
proteins), four proteinase inhibitors,  three cathepsins, six cyto- 
solic proteins, and six bovine serum proteins representing 84 
different core sequences were only detected in one allele. Pep- 
tides homologous with tubulin, an extracellular matrix-related 
protein not normally expressed in human lymphocytes but 
described as appearing on the cell surface of EBV transformed 
B cells (28), were also identified. Self-proteins thus contributed 
the large majority of bound peptides and were derived from 
both membrane proteins (which could have reached the en- 
docytic pathway by endocytosis) and from cytosolic proteins 
(which must have intersected the endocytic/class II pathway 
in some other manner). Sets of peptides with common core 
sequences and nested at either the amino- and/or carboxy- 
terminal ends were observed for 38 of these peptides. Detailed 
descriptions of the identified peptides are listed by allele in 
Tables  1-5. 
Additional peptides  were derived from a limited set  of 
secreted but not surface-expressed proteins, including endo- 
cytic processing enzymes and proteinase inhibitors that are 
present in endocytic or lysosomal vesicles. Five peptides were 
identified from the human cathepsins E and S and from a 
sequence homologous to rat cathepsin C (human cathepsin 
C has not been described). Peptides derived from two cytosol 
resident proteins  implicated in intracellular transport  and 
trafficking were also identified. A  single peptide from the 
IFN-induced guanylate-binding protein (GBP-2), distinct from 
the Rab family of canonical regulatory heterotrimeric GTP- 
binding proteins (29),  was identified, as was a nested set of 
peptides derived from Hsp 70.  Guanylate-binding proteins 
can direct vesicular traffic by stimulating endosomal fusion, 
transduce hormonal and sensory signals  across  the plasma 
membrane, and act as initiation/elongation factors during pro- 
tein synthesis (30, 31).  The Hsp 70 source protein may be 
prp72/74 (a member of the Hsp 70 family with no sequence 
available from any databank), which has been implicated in 
the intracellular assembly of processed antigen-class II com- 
plexes (32). The other four peptides from cytosolic proteins 
were from cytochrome-b5 reductase,  EBV  capsid protein, 
c-myc,  and K-ras. 
Peptides from exogenous bovine serum proteins were also 
isolated from each allele. 25 peptides representing 11 different 
core sequences that were homologous to human apolipoprotein 
B-100 were identified. The core sequences varied among al- 
leles indicative of allelic specificity.  Although the sequence 
for bovine apolipoprotein B-100 has not been described, this 
protein is the principal apolipoprotein in chylomicrons, very 
low density lipoprotein and low density lipoprotein in humans 
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Peptides derived from other proteins in bovine serum include 
fetuin (15), factor VIII, hemoglobin, complement C9, yon 
Willebrand factor, and transferrin. With  the exception of 
apolipoprotein B-100, the relative abundance of the serum- 
derived peptides was significantly lower than that observed 
for MHC-related self-peptides. 
Sequence analyses of the peptides extracted from these five 
DR alleles confirm that class II antigen processing produces 
heterogeneous-sized peptides nested at both the amino- and 
carboxy-terminal ends. The characterization of potential en- 
zymatic cleavage points was attempted by alignment of the 
flanking regions surrounding the identified peptide sequences. 
No common pattern was recognized, probably due to the 
exoproteolytic removal of amino acids from each end, and 
the shifting nature of the binding core sequences.  However, 
a marked preference for heterogeneity, both in number of 
amino acids and total number of peptides, was observed at 
the carboxy-terminal  end as compared with the amino-terminal 
end. 
Promiscuous  Self-peptides.  The ability of individual pep- 
tides to bind to multiple DR alleles is defined as promiscuity 
(also referred to in the literature as degeneracy) and has been 
previously described for antigenic peptides presented to DR- 
restricted T  cells (23, 33-35) as well as in in vitro binding 
experiments (36-40). 37 peptides derived from four promis- 
cuous self-peptide families were identified (Table 6). These 
peptides were derived from Ii, an HLA-A2-1ike sequence (de- 
scribed below), HLA-DR ot chain, and Ig g chain. Each was 
represented by a nested set of peptides similar to those de- 
Table  1.  Naturally Processed Peptides Bound to HLA-DR2 
Protein 
Source protein  category  Residues  Sequence  Length  RT  [M  +  HI+  Observed  Yield* 
HLA-DQ c~ chain  Membrane  97-119 
97-112 
HLA-DQ B chain  Membrane  42-59 
43-59 
43-57 
HLA-DR2b fl 
chain  Membrane 
FnR c~ chain  Membrane 
K + channel protein  Membrane 
Mannose binding 
protein 
MET 
GBP-2 
Apolipoprotein 
B-10011 
Membrane 
Membrane 
Cytosolic 
Exogenous 
Factor VIII  IJ  Exogenous 
min  mr  mr  pmol 
NIVIKRSNSTAATNEVPEVTVFS  23  52  2,477  2,478  -* 
NIVIKRSNSTAATNEV  16  49  1,717  1,717  -* 
SDVGVYRAVTPQGRPDAE  18  49  1,917  1,9~  14.0 
DVGVYRAVTPQGRPDAE  17  49  1,830  1,833  _s 
DVGVYRAVTPQGRPD  15  49  1,630  1,633  _s 
94-111 
94-108 
586-616 
173-190 
173-189 
RVQPKVTVYPSKTQPLQH  18  48  2,107  2,114  12.5 
RVQPKVTVYPSKTQP  15  48  1,728  1,731  -$ 
LSPl H IALNFSLDPQAPVDSHGLR  30  71  3,308  3,313  11.1 
PALHYQ 
DG I LYYYQSGGRLRRPVN  18  71  2,127  2,133  -* 
DG I LYYYQSGGRLRRPV  17  71  2,o13  2,o18  -* 
174-193 
59-81 
434-450 
I QNL I KEEAFLG I TDEKTEG  20  80  2,248  2,248  -~ 
EHH I FLGATNY I YVLNEEDLQKV  23  75  2,746  2,747  -* 
QELKNKYYQVPRKG I QA  17  81  2,063  2,074  -* 
1200-1220  FPKSLHTYAN I LLDRRVPQTD  21  71  2,485  2,491  22.6 
1200-1218  FPKSLHTYAN I LLDRRVPQ  19  71  2,269  2,277  _s 
1775-1790  LWDYGMSSSPHVLRNR  16  53  1,918  1,922  -* 
Amino acid sequences (single-letter  code) and mass determinations  are shown for peptides isolated from  HLA-DR2. All sequences  were determined 
by automated Edman degradation  using a protein sequencer  (ABI 477A). RT, retention  time from RPC separation; FnR, fibronectin  receptor;  MET, 
MET protooncogene  member of the tyrosine  kinase family of growth factor receptors; GBP-2, IFN-induced guanylate-binding  protein 2. Protein 
category  refers  to the type of source protein; membrane  refers to endogenous  membrane  associated/secretory  proteins; cytosolic  refers  to endogenous 
resident cytosolic  proteins; and exogenous  refers  to bovine serum proteins. [M + H] + refers  to the calculated  mass of the peptide in daltons, while 
the observed m/z refers to the mass in daltons determined by either a Finnigan TSQ 700 or LASERMAT mass spectrometer. 
* Yield refers to initial sequence levels of individual peptides. Total yield of peptides from a single source protein is summed. 
* A yidd <8 pmol. 
S  Yields for coeluting peptides with identical amino termini could not be distinguished. 
II Proposed bovine serum sources with sequence homology to known human proteins. 
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Protein 
Source protein  category  Residues  Sequence  Length  RT  [M  +  H] +  Obs.  Yield* 
HLA-A301  Membrane 
HLA-DR ~x chain  Membrane 
Invariant chain  Membrane 
Acetylcholine receptor  Membrane 
Glucose transporter  Membrane 
Na+ channel protein  Membrane 
CD45  Membrane 
ICAM-2  Membrane 
IFN-3' receptor  Membrane 
EBV gp220  Membrane 
EBV tegument p140  Membrane 
IP-30  Membrane 
Cyt-b5  Cytosolic 
Apolipoprotein B-10011 Exogenous 
rain  m/z  m/z  pmol 
28-?  VDDTQFVRFDSDAASQ...  ND  58  ND  ND  -* 
111-129  PPEVTVLTNSPVELREPNV  19  58  2,090  2,093  -* 
111-128  PPEVTVLTNSPVELREPN  18  58  1,991  1,990  -* 
131-149  ATKYGNMTEDHVMHLLQNA  19  73  2,173  2,179  41.5 
289-304  VFLLLLADKVPETSLS  16  69  1,745  1,750  18.5 
459-474  TFDE I ASGFRQGGASQ  16  58  1,671  1,673  -~ 
384-397  YGYTSYDTFSWAFL  14  43  1,721  1,721  -* 
1071-1084  GQVKKNNHQEDK  I E  14  43  1,667  1,667  -* 
64-76  LNKI LLDEQAQWK  13  54  1,599  1,602  12.2 
128-148  GPPKLD I RKEEKQ I M I D I FHP  21  82  2,505  2,510  25.4 
128-147  GPPKLD I RKEEKQ I M I D I FH  20  82  2,408  2,412  _s 
592-606  TGHGARTSTEPTTDY  15  43  1,593  1,593  -* 
1395-1407  KELKROYEKKLR0  13  54  1,747  1,750  -* 
38-59  SPLQALDFFGNGPPVNYKTGNL  22  82  2,350  2,353  -* 
38-57  SPLQALDFFGNGPPVNYKTG  20  82  2,122  2,124  -* 
155-172  GKFAI RPDKKSNP  I  I RTV  18  54  2,040  2,043  -* 
1276-1295  NLFLKSDGR  I KYTLNKNSLK  20  67  2,353  2,360  43.1 
1273-1292  I PDNLFLKSDGR  I KYTLNKN  20  69  2,350  2,355  27.5 
1273-1291  I PDNLFLKSDGR  I KYTLNK  19  69  2,236  2,245  _s 
1273-1290  I PDNLFLKSDGR  I KYTLN  18  69  2,107  2,097  _s 
1273-1289  I PDNLFLKSDGR  I KYTL  17  69  1,993  2,001  _s 
1276-1291  NLFLKSDGRIKYTLNK  16  64  1,910  1,911  43.8 
1276-1290  NLFLKSDGR  I KYTLN  15  64  1,782  1,786  _s 
1207-1224  YAN I LLDRRVPQTDMTF  17  67  2,053  2,059  -t 
1794-1810  VTTLNSDLKYNALDLTN  17  73  1,895  1,896  -* 
114.4 
Sequence and mass determinations  for peptides bound to HLA-DR3 are shown. Experimental  conditions, abbreviations, and notes are as listed in 
Table 1 with the following  additions: IP-30, IFN-~/-induced  protein; Cyt-b5, NADH-cytochrome  bs reductase. 
I Partial sequence not verified  by mass spectrometry. 
scribed earlier  for the allele-specific peptides.  Mass analysis 
of fractions collected adjacent to those sequenced confirmed 
the presence of additional peptides corresponding precisely 
in mass to each of the promiscuous peptides with extensions 
and/or truncations at either terminal end. 
The second most abundant set of characterized promis- 
cuous self-pepddes was derived from an HLA-A2-1ike sequence 
with residues 105-117 as the core. However, only two of the 
five cell lines studied express HLA-A2 (Priess A2/DR4 and 
23.1 A2/DR8).  Nevertheless,  HLA-A2-1ike  peptides were 
isolated from DR2 (MST cells, A3), DR3 (WT-20 cells, A30), 
and DR7 (Mann cells, A29), none of  which expresses HLA-A2 
(reconfirmed by staining with specific mAb; data not shown). 
These same peptides have also been identified from peptide 
pools extracted from DR1 expressed in the HLA-A2-positive 
cell line, LG-2 (15). This sequence, in which tryptophan 107 
is a unique residue and facilitates spectrophotometric detec- 
tion, has been found only in HLA-A2 and HLA-A69 (which 
appears to have arisen by an exon exchange involving the third 
exon of an HLA-A2 gene encoding its cx2 domain) (41). DR1 
expressed in LG-2 (HLA-A2 homozygous), HOM-2 (HLA- 
A3 homozygous), and the mutant cell lines 721.45  (HLA- 
A2-positive hemizygous deletion mutant) and 721.221 (a class 
I negative variant of 721.45,  reference 42) was purified and 
the bound peptide pools characterized. The HLA-A2-1ike pep- 
tides were found in each of the cell lines,  but in varying 
amounts (Fig. 3). Identification of these peptides was accom- 
plished by sequence and mass identity of the HLA-A2-1ike 
32  Promiscuous  and Allele-specific  Self-peptides Bound to HLA-DR Alleles Table  3.  Naturally  Processed Peptides Bound  to HLA-DR 4 
Protein 
Source protein  category  Residues  Sequence  Length  KT  [M  +  H] +  Obs.  Yield 
HLA-A2  Membrane 
HLA-Cw9  Membrane 
HLA-Bw62  Membrane 
28-50 
28-48 
28-47 
28-46 
30-48 
31-49 
28-44 
31-47 
31-45 
31-42 
28-50 
31-52 
28--48 
28-47 
28-46 
28-45 
31-48 
28-44 
30-46 
31-44 
130-150 
129-147 
130-147 
129-145 
129-144 
129-143 
129-150 
129-148 
129-146 
129-145 
VLA-4  Membrane  229-248 
229-244 
HLA-DQ3.2 B chain  Membrane  24-38 
PAI-1  Membrane  261-281 
261-278 
Cathepsin C I  Membrane  151-167 
151-166 
Ig Heavy chain**  Membrane  121-? 
Bovine hemoglobin  Exogenous  26-41 
min  mr  mr 
VDDTQFVRFDSDAASQRMEPRAP  23  61  2,639  2,641 
VDDTQFVRFDSDAASQRMEPR  21  59  2,471  2,473 
VDDTQFVRFDSDAASQRMEP  20  62  2,315  2,319 
VDDTQFVRFDSDAASQRME  19  57  2,217  2,219 
DTQFVRFDSDAASQRMEPR  19  58  2,256  2,263 
TQFVRFDSDAASQRMEPRA  19  59  2,212  2,212 
VDDTQFVRFDSDAASQR  17  58  1,957  1,963 
TQFVRFDSDAASQRMEP  17  59  1,985  1,987 
TQFVRFDSDAASQRM  15  57  1,759  1,761 
TQFVRFDSDAAS  12  57  1,343  1,343 
VDDTQFVRFDSDAASPRGEPRAP 
TQFVRFDSDAASPRGEPRAPWV 
VDDTQFVRFDSDAASPRGEPR 
VDDTQFVRFDSDAASPRGEP 
VDDTQFVRFDSDAASPRGE 
VDDTQFVRFDSDAASPRG 
TQFVRFDSDAASPRGEPR 
VDDTQFVRFDSDAASPR 
DTQFVRFDSDAASPRGE 
TQFVRFDSDAASPR 
LRSWI'AADTAAQ 
DLRSWTAADTAAQ 
LRSWTAADTAAQ 
DLRSWTAADTAAQ 
DLRSWl'AADTAAQ 
DLRSWTAADTAAQ 
TQRKWEAA 
TQRKW 
TQRKW 
TQR 
TQ 
T 
23  59  2,534  2,537 
22  57  2,490  2,491 
21  57  2,366  2,368 
20  59  2,209  2,211 
19  59  2,112  2,114 
18  59  1,983  1,987 
18  55  2,036  2,041 
17  58  1,926  1,932 
17  55  1,898  1,902 
14  55  1,597  1,604 
21  59  2,375  2,376 
19  61  2,218  2,220 
18  61  2,103  2,105 
17  62  1,904  1,909 
16  62  1,748  1,752 
15  62  1,620  1,622 
DLSSWTAADTAAQ I TQRKWEAA  22  69  2,421  2,423 
DLSSWTAADTAAQ I TQRKWE  20  70  2,278  2,285 
DLSSWTAADTAAQ I TQRK  18  69  1,963  1,966 
DLSSINTAADTAAQ I TQR  17  63  1,835  1,838 
GSLFVYN I TTNKYKAFLDKQ  20  69  2,351  2,353 
GSLFVYN I TTNKYKAF  16  69  1,866  1,868 
SPEDFVYQFKGMCYF  15  83  1,861  1,862 
AAPYEKEVPLSALTN I LSAQL  21  69  2,228  2,229 
AAPYEKEVPLSALTN I LS  18  69  1,916  1,917 
YDHNFVKA I NADQKSWT  17  74  2,037  2,039 
YDHNFVKA I NADQKSW  16  74  1,936  1,938 
GVYFYLQWGRSTLVSVS...  ND  70  ND  ND 
AEALERMFLSFPTTKT  16  83  1,842  1,836 
pmol 
_$ 
13.5 
28.9 
51.7 
12.5 
_$ 
_s 
_$ 
_$ 
106.6 
_s 
_$ 
_$ 
_$ 
_$ 
_$ 
11.0 
_$ 
_5 
_S 
147.2 
_$ 
_$ 
_$ 
16.8 
175.0 
-I 
13.6 
_$ 
84.8 
98.4 
_$ 
20.1 
_/ 
-t 
-t 
Sequence and mass determinations for peptides bound to HLA-DR4 are shown. Experimental conditions, abbreviations, and notes are as listed in 
Table I with the following additions. VLA-4, a cell surface heterodimer in the integrin superfamily of adhesion receptors; PAI-1, plasminogen activa- 
tor inhibitor 1. 
ql Proposed human protein source with sequence homology to the reported rat cathepsin C  sequence. 
"" Partial sequence not verified by mass spectrometry. T
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HLAoA2 ligr P~'!~i~ 
\ 
SO  SO 
B0  SO 
.......... J[  [~| 
6O  SO  letgure  3.  Resined-phase  HPLC 
separation  profiles  of  Peptides 
bound  to  HLA-DI~I  purified 
from both HLA-A2-positive and 
-negative  cell  lines.  Chroma- 
tographic peaks  containing  the 
HLA-A2-1ike peptides  are easily 
discerned by their prominent 277- 
nm UV absorbance due to tryp- 
tophan.  HLA-A  alleles  of  the 
homozygous cell lines are: LG-2 
(HLA-A2), HOM-2 (HLA-A3), 
721.45  (HLA-A2  hemizygous), 
and 721.221 (class I-negative de- 
letion mutant). 
rived from nonpolymorphic  regions of their respective source 
proteins. A set of MHC-related peptides was derived from 
the HLA-DR o~ chain (positions 182-194),  common to all 
DR alleles. Three DR a  peptides varying in length from 
truncations at the carboxy terminus have been sequenced from 
four of the five DR isotypes.  These peptides are similar in 
composition to those derived from Ii in that both groups 
have a relatively high proline content and no aromatic residues, 
but neither of these two properties are shared by the other 
two promiscuous sdf-peptides. The only peptides isolated 
from multiple DR isotypes not associated with the MHC 
were derived from the Ig ~c chain (present in varying quanti- 
ties on the surface of most of the cell lines from which the 
DR molecules were purified; data not shown). 
Peptide Binding  to Surface-expressed HLA-DR 
Synthetic peptide analogues representing promiscuous and 
allele-specific peptides were used in surface-binding assays. 
Before biotinylation each synthetic peptide was observed to 
have the same RPC retention time as the naturally processed 
extracted self-peptide  (data not shown). Each peptide con- 
tained a  single biotin  attached via a  22-A  spacer  to  the 
amino terminus. The cell lines used for the binding assay (23, 
24) were those from which the respective DR isotypes were 
purified. As a negative control, the class II deletion mutant 
T2 was used to monitor nonspecific binding of peptide to 
the cell surface. 
Direct binding of biotinylated peptide to class II MHC 
molecules on the surface of fixed cells was detected by FITC- 
streptavidin using flow cytometry. Peptide concentrations be- 
tween 6.25 and 100 #M were used to measure relative binding 
(Table 7). Specific peptide binding could be blocked by mAb 
L243 before addition of peptide (Fig. 4). The biotinylation 
of the HLA-A2-1ike  peptide 103-117  interfered with the 
normal mode of binding for this peptide; however, the non- 
biotinylated synthetic peptide did competitively inhibit the 
specific binding of the other peptides. Similarly, competitive 
inhibition using an excess of nonbiotinylated peptide was ob- 
served for each peptide (data not shown). Thus, it appears 
that the promiscuous peptides were capable of binding to 
multiple DR alleles. In contrast, strict allelic specificity was 
demonstrated by the apolipoprotein B-100 peptide 1273-1291; 
it bound only to DR3.  No specific binding of any of the 
peptides to the class II-negative cell line, T2, was observed. 
labeled peaks (data not shown). Experiments to characterize 
a putative locus encoding the HLA-A2-1ike sequence in HLA- 
A2-negative cells are underway. 
The peptides derived from Ii varied in length from 15 to 
25 residues with a common core sequence at position 107-120, 
and were found in three of the five alleles studied here. They 
were prominent peptides in each of the alleles in which they 
were found. An interesting physical characteristic  of the Ii 
peptides is their lack of aromatic amino acids, especially since 
this feature is prominent in several  putative DR-binding motifs 
(39,  43-46). 
The two remaining sets of promiscuous peptides both de- 
Discussion 
Four properties illustrate the functional dichotomy  between 
class I and II proteins with respect to peptide binding: (a) 
although both class I  and II proteins assemble in the en- 
doplasmic reticulum, only class I binds peptides before reaching 
the golgi; (b) cellular trafficking ensures that class II mole- 
cules travel a pathway to the cell surface separate from that 
of class I and encounter different types of source proteins in 
the endocytic structures where peptides are loaded; (c) struc- 
tural differences in the binding groove/pocket geometry define 
the sizes ofpeptides from a large random pool that can bind 
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 Table  7.  Surface Staining of EBV-transformed Lyraphoblastoid Cell Lines 
Cell lines  Ii (97-120)  Ig x (188-202)  HLA-DR a  (182-198)  Apo B (1273-1291) 
LG-2 (DR1)  123  191  345  50 
MST  (DR2)  288  178  148  18 
WT-20 (DR3)  170  174  176  450 
Priess  (DR4)  215  189  189  57 
Mann (DR7)  288  171  nd  50 
23.1  (DR8)  213  221  172  19 
T2 (no DR)  35  42  39  40 
Peptide binding to cell surface expressed class II MHC molecules. The cell lines used to produce the HLA-DR molecules in this study were incubated 
with biotinylated synthetic peptide and specific binding was measured by flow cytometry. The data are presented as the relative mean log fluorescence. 
Promiscuous peptides were determined to bind to all six surface expressed DR alleles, while the apolipoprotein B-100 peptide 1273-1291  was found 
only to bind DR3-positive cells. 
class II (10-34 residues) rather than class I molecules (8-11 
residues); and (d) since the size distributions of bound pep- 
tides are different, the antigen processing machinery used to 
supply peptide for each is likely to be different. Peptides from 
antigen produced endogenously are primarily presented by 
class I, while peptides from exogenously administered an- 
tigens are presented by class II MHC molecules (47). How- 
ever,  class II MHC molecules also present peptides derived 
from proteins synthesized by the APC itself, although pri- 
marily derived from source proteins translated with signal 
peptides (membrane associated or secretory proteins) (48-55). 
Class II molecules can in addition bind endogenous peptides 
derived from cytosolic source proteins, but only after such 
proteins enter the class II processing compartment by either 
180 
r 
16o 
140 
g  12o  ,v 
100 
80  "O 
N  60 
~  4o 
N  20 
Figure 4. 
-0-  HLA-DR8 
O  HLA-DR8/L243 
HLA-DR3  243 
100  50  25  12.5 
Peptide Concentration (pM) 
Ii  peptide  97-120-specific  binding  to  surface-expressed 
HLA-DR was determined by direct measurement of added biotinylated 
peptide using flow cytometry. APC were preincubated with either the 
anti-DR mAb L243 to sterically obstruct the peptide binding site or a 
mock buffer before the addition of biotinylated peptide, li peptide was 
blocked at all concentrations measured,  representative  of the L243 anti- 
body-induced blocking of peptide binding to surface-expressed DR alleles, 
translocation or autophagy (56, 57). The relative proportion 
of class II-bound peptides derived from these sources has not 
been dear. 
The peptides bound to class II MHC molecules purified 
from APC grown in culture without exposure to "antigen" 
are described here. Peptides derived from endogenous pro- 
teins (both membrane associated/secretory and cytosolic pro- 
teins) and exogenous serum sources were identified. If the 
peptides presented by EBV-transformed B cells grown in vitro 
are truly representative, then >85%  of the peptides bound 
to class II MHC molecules in vivo are derived from endoge- 
nous self-proteins. The frequency of the different types of 
peptides bound to the DR alleles examined is represented in 
Fig. 5. The predominant endogenous peptides were derived 
from MHC-related  source proteins, supporting earlier ob- 
servations on sequenced peptides bound to DR1 and H-2A a 
(13,  15) and functional work describing the presentation of 
both class I- and dass II-derived peptides to CD4 + T  cells 
(53, 58, 59). Interestingly, only a single MHC-related pep- 
tide was identified as bound to either DRll/DRw52  or H2- 
A k, while none at all were reported among the peptides se- 
quenced from H-2A'  or H-2E  b, even though these MHC 
molecules were purified from similar APC. However, only 
a limited number of peptides were analyzed in these studies 
(12,  14, 46, 60).  Cell-specific differences in class II antigen 
processing or protein immunoaffinity purification could also 
have introduced peptide bias. 
These peptide sequences may also farther our understanding 
of class  II antigen processing in vivo. Only 27 of the 201 
sequenced peptides were <15 residues in length, even though 
in vitro experiments have shown minimal required peptide 
lengths of 9-10 residues (1, 34, 38, 45, 61), thus supporting 
the notion that dass II molecules protect bound peptides from 
proteolytic degradation in vivo (15) as well as in vitro (62, 
63). The identification of peptides containing a single N-acetyl- 
glucosamine (see Table 5) confirmed an earlier in vitro func- 
tional study, but more importantly further illustrates the role 
of lysosomal degradation in antigen processing (64, 65). Since 
40  Promiscuous  and Allele-specific Self-peptides Bound to HLA-DR Alleles HLA-DR1  HLA-DR2  HLA-DR3 
[]exogenous  proteins 
membrane 
~  associated 
secretory 
proteins 
[]  MHC- 
related prot 
[] 
HLA-DR4  HLA-DR7  HLA-DR8 
Figure 5.  Relative  frequency  and source  of peptides  bound to  six 
HLA-DR alleles. Source proteins were divided into three groups; exoge- 
nous serum proteins, endogenous membrane assoeiatedAecretory  proteins, 
and endogenous cytosolic proteins, and the number of sequenced peptides 
(not the molar abundance) for each allele,was plotted.  The DR1 peptides 
were as previously described (15). Although this representation is only 
based on the 223 peptides sequenced from six DR alleles (between  1.6 
and 5% of the estimated total number of peptides bound to any single 
class 11 allele), it appears to show a consistent preference for certain types 
of source proteins. The predominance of MHC-related peptides is high- 
lighted as a subset of the membrane-associated/secretory source protein 
group. 
neither the immunoaffinity  purification nor the mild acid ex- 
traction procedure altered  the glycosylation of the class II 
a  or/5 chains (data not shown), the complex carbohydrate 
originally attached to the peptide must have been enzymati- 
cally cleaved in a lysosomal carbohydrase-containing compart- 
ment. Further corroboration of lysosomal processing was 
demonstrated by the identification of cathepsin C-, E-, and 
S-derived  peptides  and  the  observation  of  17  cysteine- 
containing peptides, presumably generated after lysosomal 
disulfide reduction (66).  Finally, the marked preference for 
heterogeneity at the carboxy-terminal end is consistent with 
the concerted action of the endosomal proteases  cathepsin 
D and B (67). However, because no fixed cleavage sites were 
determined,  additional  exo-  and  endoproteases  such  as 
aminopeptidase N  should also continue to be considered as 
part of the processing machinery. 
Allelic Specificity in Peptide Binding.  Allelic specificity was 
suggested by distinct HPLC profiles of peptide isolated for 
41  Chicz  et al. 
each allele and by the identification for single DR alleles of 
84 peptides with different core sequences. In addition to the 
promiscuous class I- and class II-derived peptides, 41 other 
peptides from six different class I molecules and 15 peptides 
from eight different class II molecules were processed  and 
efficiently bound by the DR alleles. Although the predomi- 
nant peptides were derived from MHC-related molecules, pep- 
tides in sufficient quantity for sequence analysis  were identified 
from 52 source proteins not associated with the MHC. The 
majority of these were from integral membrane proteins ex- 
pressed on the cell surface or serum-derived proteins. If non- 
MHC-related membrane-bound proteins were internalized 
and degraded, the peptide products would travel through the 
endocytic pathway and encounter DR molecules en route to 
the cell surface in endocytic vesicles (68-70). Similar source 
proteins were described for the peptides isolated from mu- 
rine H-2A alleles (12, 13, 60). Of the few cytosolic peptides 
identified, a partial sequence overlap was found with the Hsp 
70 self-peptide bound to H-2A (14), while a different Hsp 
70 peptide sequence was reported from DR11/DRw52 (46). 
These peptides may be allele specific since no common se- 
quences from these peptides were observed in more than one 
DR isotype. 
Apolipoprotein B-100 from serum in the medium was the 
most abundant exogenous peptide source protein. This prob- 
ably occurred as a result of the efficient internalization of 
apolipoprotein B-100 by the LDL receptor in clathrin-coated 
pits (71) and subsequent delivery of the protein to the endo- 
somes.  The binding  specificity  for  apolipoprotein B-100 
1273-1291 was determined to be limited to DR3, but addi- 
tional synthetic peptides must be made to confirm the spec- 
ificity of the remaining 10 apolipoprotein B-100 core sequences. 
This is especially significant in light of two partial sequence 
overlaps from apolipoprotein B-100 observed in DR2/DR3 
and DR7/DR8, respectively. These sequences cannot be elim- 
inated  as  candidates  for  promiscuity until  their  binding 
specificity is tested with synthetic analogues.  Interestingly, 
an apolipoprotein B-100 peptide sequence not isolated from 
any  of  the  five  alleles reported  here  was  identified  in 
DRll/DRw52 (46), further suggestive of allele specificity. 
Additional sequence analyses and/or binding studies with syn- 
thetic peptides should determine whether all of the allele- 
specific observations represent truly specific  binding to different 
DR alleles. 
Promiscuit  7 in Peptide Binding to Class II MHC Molecules. 
The identification of peptides bound to different DR alleles 
and confirmation of their binding capacity using synthetic 
peptides demonstrated the promiscuity of four of the self- 
peptides. The remarkable efficiency of both processing and 
binding of promiscuous self-peptides may suggest a physio- 
logic role for these peptides in modulation of the immune 
response.  Perhaps they ensure that only antigenic peptides 
with sufficient affinity are presented to CD4 + T cells. Rec- 
ognition of antigen has been demonstrated to be extremely 
sensitive, with 80-500 immunogenic class II/peptide com- 
plexes being sufficient for T cell stimulation (72, 73). Thus, 
a few immunologically active peptides could overshadow a 
plethora ofpeptides (estimated to be between 650 and 2,000; references 13 and 15) bound to surface-expressed MHC mol- 
ecules. Since overstimulation by antigen can induce periph- 
eral tolerance (74-78), these self-peptides may serve not only 
as competitors to ensure that only antigenic peptides capable 
of long half-lives bind, but also to prevent overpresentation 
of a foreign peptide epitope in vivo. Generation of self-peptides 
as immunomodulators could be an efficient mechanism within 
the cell since the source proteins are available  in suffident 
concentration and the immune system in general would have 
developed tolerance to these sequences during maturation. 
Perhaps the most interesting set of promiscuous self-peptides 
are those derived from Ii. Ii forms a complex with class II 
MHC molecules early during biosynthesis and has several roles 
in antigen processing/presentation. Ii functions as a chaperone, 
blocks premature peptide binding, and affects class II intra- 
cellular trafficking (79-86). Could Ii have evolved within its 
primary structure an immunomodulatory peptide sequence 
capable of high affinity binding to the dass II binding groove? 
Is that sequence the site at which intact Ii binds to class II 
MHC molecules initially? Ii is a type II transmembrane gly- 
coprotein with its amino terminus as the cytoplasmic tail. 
There are 34 residues between the ER lumenal side of its 
transmembrane domain (residue 72) and the beginning of 
the core sequence of the Ii-nested set of peptides bound to 
class II MHC molecules (residue 106). This length would 
be adequate for the Ii polypeptide to reach the cleft at the 
top of the class II MHC molecule, estimated to be at least 
45 A  from the membrane (J. Brown, personal communica- 
tion) as an ce-helix (51  ~  at  1.5  A/amino add), or more 
than  adequate  as  an  extended polypeptide  (119  A  at  3.5 
/amino acid for a B-pleated sheet).  Alternatively,  the Ii 
peptides may be formed efficiently by proteolysis of Ii in the 
endosomes and then bind to c~/~ dimers. In either case, since 
proteolytic cleavage effidently dissociates Ii from class II in 
the antigen processing compartment, the final role of Ii may 
be to provide high affinity peptides to serve as competitors 
during the binding of antigenic peptides. At present, the ad- 
ditional  possibility  that  these  Ii peptides act  as  allosteric 
effectors and bind to the c~/~ dimers at some site other than the 
binding cleft is still imaginable. Regardless of how peptide 
binding occurs, both the high affinity (15,  87) and promis- 
cuous binding of the Ii peptides to DR molecules are clearly 
evident. Furthermore, the processing machinery for the pro- 
teolysis of Ii does not differ significantly among cell lines, 
since the same nested set of peptides was isolated from mul- 
tiple cell lines, as well as DR1 (15), and in antigen-processing 
mutants expressing DR3 (87, 88). Interestingly, homologous 
Ii peptides from two different H-2A alleles  have also been 
identified (12,  13),  suggesting a universal function for the 
relatively well-conserved high af~nity peptides derived from 
this molecule and bound to class  II proteins. 
Peptides derived directly from class II MHC molecules by 
proteolysis are also among the naturally processed bound pep- 
tides. A set of peptides from the conserved DR oe chain ex- 
hibited promiscuous binding like the Ii peptides. Similarly, 
a peptide set from the nonpolymorphic murine homologue, 
H-2E oe chain, was identified as bound to H-2A molecules 
that were immunoaffinity purified from tither cultured B cells 
(12, 13) or spleen cells, thus demonstrating that peptides from 
MHC-rdated  proteins  also  bind  to  class  II  molecules  in 
vivo (60). 
The set of class I MHC-related promiscuous peptides is 
by far the most enigmatic. Although this peptide set is dearly 
related to HLA-A2 (or HLA-A69, which contains the same 
c~2 domain as HLA-A2), it was also found in cell lines that 
were HLA-A2 negative. This set of peptides was also present 
in the class II molecules purified from the deletion mutant 
721.221, which lacks expression of HLA-A, -B, and -C mol- 
ecules, although some dass I loci are still present (42). Thus, 
a putative locus encoding the HLA-A2-1ike protein could be 
located within  the class  I  subregion  of the  MHC.  Exon 
shuffling in vivo can generate novel HLA class I molecules 
(89), and one possibility for the source of the HLA-A2-1ike 
self-peptides could be a nonfunctional pseudogene encoded 
within this region of the MHC.  The reduced yield of the 
A2-1ike peptide in 721.221 could be due to a deletion in a 
regulatory element or promoter region located in the class 
I MHC loci, since large gene deletions exist in this mutant 
cell line.  The amount of identified HLA-A2-1ike peptides 
varied among the DR alleles,  suggesting two possibilities: 
(a) the number of fractions sequenced was too small to permit 
statistical evaluation; or (b) the concentration-dependent equi- 
librium essential for peptide binding was perturbed by either 
poor processing of the HLA-A2-1ike molecule, resulting in 
less peptide generated or more efficient processing of other 
protein sources. 
The only set of promiscuous binding peptides derived from 
a non-MHC-related protein was from the Ig K chain. Rela- 
tively high concentrations of this protein would be expected 
to enter the endocytic pathway since its role is to capture 
intact antigen on the surface of APC and traffic it to endo- 
somes. Presentation of endogenously processed Ig light chain 
by class II MHC molecules has been demonstrated in B lym- 
phoma cells with T  cell stimulation assays (49,  54) and by 
sequence analysis  of bound peptides (60). The high affinity 
binding of the Ig K synthetic analogue to six DR alleles (in- 
cluding DR1 from I/3-2, which is ), positive) supports the 
binding promiscuity even though Ig K peptides were only 
isolated from two  alleles.  The recent  sequence analysis of 
DRll/DRw52-bound peptides also reported this same pep- 
tide (46),  further  supporting its promiscuity. 
The ability of peptides to bind multiple DR alleles must 
be dependent on the composition and location of several key 
amino acids within the primary structure.  Peptide binding 
to class I MHC molecules has been demonstrated to primarily 
involve hydrogen bond networks between the MHC mole- 
cule and peptide backbone atoms. If a similar mechanism can 
be extended to peptide binding in class  II molecules, then 
side chain exclusion in the binding cleft region could account 
for peptide selectivity.  Hence,  steric  hinderance could be 
avoided by  promiscuous  peptides  possessing  a  minimum 
number of bulky side chain residues leading to high affinity 
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posal based on synthetic peptide analogue studies has been 
made (1). 
Motifs for Binding  of Peptides  to HLA-DR  Alleles.  Strict 
allele-specific  binding motifs, as defined for dass I MHC mol- 
ecules, may not exist for dass II-bound peptides. Identification 
of class I motifs was aided: (a) by the relatively small size of 
the bound peptides (nonamers); (b) the fact that the majority 
of these peptides have their amino and carboxy termini fixed 
within the A and F pockets of the class I MHC molecules; 
and (c) the uniform length of the peptides bound to the al- 
leles initially studied. The problem of deducing motifs from 
sequence information is more difficult for class II molecules. 
Bound peptides vary in size (10-34 residues) and are repre- 
sented by nested sets with varying numbers of flanking residues 
added at either the amino or carboxy termini, making in- 
terpretation of pooled sequencing data nearly impossible. Thus, 
the longer peptides do not appear to have an end anchored 
within the binding cleft of class II MHC molecules and may 
extend outside the cleft at either or both ends. The minimal- 
length peptide could contain a motif within its core region 
(9-10 residues), but the core and its anchor residues may be 
located at various positions within different peptides. Thus, 
the identification of motifs from sequence information alone 
is difficult and some additional data are required, such as 
binding studies varying the length and composition of the 
peptides and even more definitively  (and with correspond- 
ingly greater difficulty) refined crystallographic information 
using single peptide complexes (90-92). 
Prior attempts at proposing DR binding motifs using var- 
ious experimental methods have generated conflicting con- 
clusions (15, 24, 39, 43, 45, 93-95). For example, aside from 
the probable presence of a hydrophobic residue important in 
anchoring the amino-terminal region of the peptide, neither 
of the motifs recently proposed for DR3 (94, 95) fits all of 
the naturally processed peptides found in this molecule (Table 
2),  illustrating the difficulty of assigning motifs based on 
limited sequence information. 
With these limitations, can any information relating to 
preferred amino acids be obtained from the sequences of the 
naturally processed peptides bound to the different DR al- 
leles? The peptide is likely to be oriented with its amino ter- 
minus at the left hand end of the binding cleft, as it is usually 
represented, and its carboxy terminus at the right hand end 
(44), as in class I MHC molecules. The left hand end of the 
deft is composed mainly of residues contributed by the non- 
polymorphic DR ot chain. A hydrophobic pocket may exist 
in this region, for example, in the region of DR oe F26, F54, 
and F51 (equivalent to Y59 in the A pocket of class I mole- 
cules) and DR B G86 (equivalent to Y171) (96). The diallelic 
polymorphism of residue 86 (G or V in different alleles) in 
the/3 chain may affect this pocket, and could well contribute 
to the size of the pocket, which might influence whether 
a large hydrophobic amino acid (I, L, M, or V) or an aro- 
matic residue (F, Y, or W) could be accommodated in this 
region (see Fig. 3 C in reference 44). Analysis of the minimum 
core sequences from Tables 1-6 reveals that there is a prefer- 
ence for hydrophobic residues near the amino-terminal end 
Table  8.  Sequence Alignment of Allele-specific Preferred Amino Acids 
Allele  Sequence alignment  Conformity 
% 
ixxxxxxxxx~  70 
DR2a/DR2b  (i  +  10) 
i  =  I,  L,  or  V  4  =  H,  K,  or R  (7/10 core sequences) 
ixx~  81 
DR3/DRw52  (i  +  3) 
i  =  F,  I,  L,  V,  or Y  ~  =  D,  N,  Q,  or T  (13/16 core sequences) 
ixxxxxxx~  88 
DR4  (i  +  8) 
i  =  F,  L,  or  V  ,~  =  iV,  Q,  S,  or  T  (7/8 core sequences) 
ixxxx~  87 
DR7  (i  +  5) 
i  =  F,  I,  L,  V,  or  Y  ~  =  IV,  S,  or  T  (13/15 core sequences) 
ixxx~  73 
DR8  (i  +  4) 
i  =  F,  I,  L,  V,  or  Y  ~  =  H,  K,  or R  (24/33 core sequences) 
The minimum core sequences from the allele-specific bound peptides (Tables 1-5) were aligned to determine the existence of any prominent amino 
acids/positions. Conformity refers to the percentage of identified sequences in exact alignment. The spacing between key residues is listed under 
the alignment, with i referring to the index position for the listed hydrophobic residues, and I referring to the preferred residues at the designated position. 
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tation of bound peptides. In fact, <1%  of the bound pep- 
tides are without some type of hydrophobic residue in the 
amino-terminal third of any given minimum core sequence. 
Allele-specific preferences for peptide residue content and 
location are not obvious. Six class II allele-specific binding 
motifs have been proposed by correlating sequence analyses 
from identified bound peptides with those of synthetic ana- 
logue studies (13, 15, 46, 60). However, in each instance there 
are peptides that bind to the particular  class  II molecules 
without an absolute compliance to the proposed preferences. 
To investigate if preferred residues exist in the peptides bound 
to individual alleles, sequence alignments were completed on 
the minimum core sequences for the peptides in Tables 1-5 
(10,  16, 8,  15, and 33 sequences, respectively). The confor- 
mity varied from a 70% alignment in DR2 (7/10 peptides, 
perhaps due in part to the minor contamination of DR2a- 
bound peptides) to an 88% alignment in DR4 (7/8 peptides), 
with no set of allele-specific peptides completely conforming 
to  a  strict  amino acid position preference (Table 8).  It is 
noteworthy that the distance between the index position (i) 
and the preferred residue (4) varied between alleles, implying 
that this spacing may in part contribute to allele-specific peptide 
binding. The promiscuous self-peptides,  demonstrated to bind 
to all six DR alleles, also varied in alignment conformity from 
60 to 100% (the worst alignment was again observed with 
DR2).  Thus, it appears that class II molecules govern pep- 
tide binding by subtle differences in peptide composition rather 
than by strictly defined side chain requirements. This con- 
clusion is supported by the identification of antigenic pep- 
tides capable of binding to multiple DR alleles (23, 33-39) 
as well as the promiscuous self-peptides identified in this report. 
As an alternative to using synthetic peptides and inferring 
that these findings are reflective of peptide binding in vivo, 
we have chosen to  analyze those peptides that  have been 
processed and bound to MHC molecules within cells. Thus, 
in addition to the identification of the bound peptides, much 
can be learned about the repertoire of presented antigen and 
the machinery involved in antigen processing. In contrast to 
the peptides bound to class I MHC proteins, dass II-bound 
peptides do not have specific side chain requirements at pre- 
cise distances from the termini, suggesting that the overall 
binding energy is provided by the sum of cooperative inter- 
actions between the peptide backbone and the deft and does 
not  involve  the  peptide  termini  per  se.  Although  allele 
specificity surely exists, the identification of promiscuous self- 
peptides (capable of binding to multiple alleles) suggests that 
rigid alhle-specific motifs for class II molecules do not exist, 
thus  permitting  a  broad  binding  specificity.  Perhaps  this 
promiscuous binding both modulates the presentation of for- 
eign antigens during an immune response and also broadens 
T cell tolerance to self-peptides during thymic development. 
Finally, the substantial amount of MHC-related bound pep- 
tide (both in terms of relative abundance and the presenta- 
tion of peptides derived from the three major isotypes found 
among class  I and II molecules) must be considered when 
interpreting alloreactivity and may have significant implica- 
tions for transplantation immunology. 
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